Pramodini Medicare Limited is set to come to the public market with its initial public offer, or IPO. The company operates in the diagnostic services space and has reported strong growth in revenue and profit in recent financial periods. At the same time, its business has a high level of dependence on radiology, one state, government-linked projects and a major customer.
The IPO has attracted attention because of its reported profit growth and high EBITDA margin. However, strong financial numbers alone do not establish that an IPO is cheap or suitable for every investor. The price paid for the shares, the quality of earnings, customer concentration, business dependence and future growth plans also matter.
This article gives a simple analytical view of the Pramodini Medicare IPO. It uses the reported figures and does not treat any future share price, allotment outcome or return as certain. Market prices can move sharply after an IPO, and investors can lose part or all of their capital.
IPO Details at a Glance
The Pramodini Medicare IPO is an SME issue. The current reported price band is ₹110 to ₹118 per share, with a lot size of 1,200 shares. The IPO is scheduled to open on 12 August 2026 and close on 14 August 2026. The reported allotment date is 17 August 2026, while the expected listing date is 19 August 2026.
| Particular | Reported detail |
|---|---|
| IPO open date | 12 August 2026 |
| IPO close date | 14 August 2026 |
| Price band | ₹110–₹118 |
| Lot size | 1,200 shares |
| Allotment date | 17 August 2026 |
| Expected listing date | 19 August 2026 |
| Issue size | ₹69.04 crore |
| Earlier fresh issue figure cited | ₹45.15 crore |
| Business | Diagnostic services |
| FY26 revenue | ₹62.29 crore |
| FY26 PAT | ₹17.38 crore |
| FY26 EBITDA margin | 49.61% |
There is an important point about the issue size. Earlier material referred to a fresh issue of ₹45.15 crore. More recent IPO data reports a total issue size of ₹69.04 crore, with a fresh issue and an offer for sale component. Therefore, investors should rely on the final offer document and the latest exchange information for the final structure.
Price Band and Minimum Amount
The price band stands at ₹110 to ₹118 per share. One lot has 1,200 shares. At the lower price of ₹110, one lot has a value of ₹1,32,000. At the upper price of ₹118, one lot has a value of ₹1,41,600.
However, the minimum application amount shown in current IPO data is ₹2,83,200 at the upper price. This indicates that the minimum SME IPO application requires two lots rather than one. This point is important because an investor may otherwise assume that ₹1,41,600 is the minimum amount required. Current IPO data lists the minimum investment at ₹2,83,200.
| Calculation | Amount |
| 1 lot at ₹110 | ₹1,32,000 |
| 1 lot at ₹118 | ₹1,41,600 |
| 2 lots at ₹118 | ₹2,83,200 |
| Reported minimum application | ₹2,83,200 |
This relatively high minimum application is a normal point to consider in an SME IPO. It can create a higher capital requirement than a typical mainboard IPO. Investors should therefore assess the amount at risk before they submit an application.
Revenue Growth Shows a Positive Trend
The reported financial numbers show clear growth in the company’s business. Revenue rose from ₹35.23 crore in FY24 to ₹62.29 crore in FY26. PAT also rose from ₹6.93 crore in FY24 to ₹17.38 crore in FY26.
This is a positive feature because revenue growth alone is less useful if profit does not rise at a similar pace. In Pramodini Medicare’s reported figures, both revenue and profit moved higher.
| Financial measure | FY24 | FY26 |
| Revenue | ₹35.23 crore | ₹62.29 crore |
| PAT | ₹6.93 crore | ₹17.38 crore |
| EBITDA margin | — | 49.61% |
The increase in PAT is especially notable. However, past growth should not be treated as proof of future growth. The company still has to maintain its business volume, pricing, margins and customer base after the IPO.
High EBITDA Margin Needs a Closer Look
The reported FY26 EBITDA margin is 49.61%. On the surface, this is a strong margin. It suggests that the company has reported a high level of operating profit compared with revenue.
A high margin can be a useful sign, but it should not be viewed alone. The quality of that margin matters. Investors should study the nature of the company’s contracts, the cost of equipment, employee costs, depreciation, finance costs and the share of revenue from government-linked arrangements.
The diagnostic sector can also require regular investment in medical equipment and technology. As the company expands, its cost structure may change. A high margin in one period may not remain at the same level in future years.
For this reason, the 49.61% EBITDA margin is best viewed as a positive reported figure rather than a promise of future profitability.
The Business Has a High Radiology Dependence
One of the biggest risks is the company’s dependence on radiology. The reported figures show that 97.05% of FY26 revenue came from radiology.
This is a very high level of concentration. It means the company has limited revenue diversity across different diagnostic services.
If radiology demand remains strong, this focus may support the company. But if there is a change in pricing, technology, competition, equipment cost, regulation or customer demand in this area, the effect on revenue could be significant.
The company may seek to expand its service base over time, but the present revenue mix remains an important risk factor.
Geographic Dependence Is Another Risk
The company also has a high dependence on Andhra Pradesh. The reported data states that 61.90% of FY26 revenue came from Andhra Pradesh.
This creates geographic concentration. A business with revenue spread across many regions may have more protection from a problem in one state. In contrast, a large share from one state can expose the company to local policy changes, contract changes, competition or changes in healthcare demand.
This does not mean that the company will face such problems. It simply means that the level of geographic dependence deserves attention before a decision.
Government PPP Revenue Needs Attention
Another important point is the company’s exposure to government public-private partnership, or PPP, arrangements. About 54.19% of revenue is reported to have come from government PPP arrangements.
Such contracts can provide a stable business base when they remain active and profitable. At the same time, contract renewal, payment terms, government policy and project conditions can affect future revenue.
Therefore, the government-linked share of revenue can be both a business strength and a concentration risk. The actual terms and duration of these contracts are more important than the revenue percentage alone.
Customer Concentration Is High
The company also has a major customer concentration issue. The largest customer contributed 44.17% of revenue, based on the reported figures.
A single customer at this level can have a meaningful effect on the company’s results. If the relationship continues, it can support revenue visibility. If the customer reduces its business, changes its contract or does not renew an arrangement, the effect could be material.
This is one of the main reasons why investors should not assess the IPO only through revenue growth and profit growth.
Expansion Plans Could Support Future Growth
The company plans to use IPO proceeds for business expansion and medical equipment. One proposed plan relates to a new centre in Bangalore.
If the new assets generate adequate revenue and profit, the expansion could improve the company’s scale. A larger network may also help the company reduce some of its current geographic dependence over time.
However, expansion always carries execution risk. A new centre requires capital, staff, equipment, customers and effective operations. The actual return on the new capital may differ from the company’s expectations.
Therefore, the proposed use of IPO proceeds is positive in principle, but the final result will depend on execution.
The IPO Is Not a Simple Low-Risk Opportunity
The reported financial performance may look attractive, but this does not make the IPO a low-risk opportunity.
There are several factors that need attention. The company has high dependence on radiology. A large part of revenue comes from Andhra Pradesh. Government PPP arrangements account for a substantial share of revenue. One major customer also contributes a large share of total revenue.
These factors can make the business more sensitive to changes in a small number of areas.
The issue is also an SME IPO. SME shares can have lower liquidity than large listed companies. After listing, the share price may not always move in the same way as the company’s operating performance. Investors should also consider the possibility of a wide difference between buying and selling prices.
Valuation Matters More Than the Story
The price band of ₹110 to ₹118 is important because the same company can look attractive or expensive at different prices.
A company with strong profit growth may still be expensive if the IPO price already reflects a large part of its expected future growth. On the other hand, a company with business risks may still have value if the price provides enough margin for those risks.
The reported FY26 PAT of ₹17.38 crore provides a useful base for valuation analysis. However, the exact post-IPO share count and final capital structure should be taken from the final offer document before a precise P/E calculation.
Investors should also compare the valuation with listed diagnostic companies. Such a comparison should not be treated as exact because business models, scale, geography, margins and contract structures can differ.
What the Numbers Say
The overall picture is mixed rather than clearly positive or negative.
| Factor | Analytical view |
| Revenue growth | Positive |
| PAT growth | Positive |
| FY26 EBITDA margin of 49.61% | Positive on reported figures |
| Radiology share of 97.05% | High concentration risk |
| Andhra Pradesh share of 61.90% | Geographic risk |
| Government PPP share of 54.19% | Contract concentration risk |
| Largest customer share of 44.17% | Customer concentration risk |
| Expansion plans | Potential growth support |
| SME structure | Higher liquidity and volatility risk |
| IPO price | Needs valuation-based assessment |
This table shows why the IPO needs a balanced view. The company has strong reported growth, but the revenue base is concentrated.
A Careful View for Investors
For a long-term investor, the main question is not whether the IPO can produce a positive first-day return. The more useful question is whether the company can maintain revenue growth, protect its margins, reduce concentration risk and earn a good return on the new capital.
For a short-term investor, the situation is different. IPO demand, market sentiment, subscription levels and the gap between the issue price and the market price can affect the result. These factors are difficult to predict with certainty.
Any decision should also account for the minimum capital requirement. At the current upper price of ₹118, the reported minimum application is ₹2,83,200. That is a meaningful amount for many investors and should not be treated as a small speculative position.
Final Assessment
Pramodini Medicare presents a combination of strong reported financial growth and clear business concentration risks. Revenue rose from ₹35.23 crore in FY24 to ₹62.29 crore in FY26, while PAT rose from ₹6.93 crore to ₹17.38 crore. The reported FY26 EBITDA margin of 49.61% is also notable.
At the same time, 97.05% of FY26 revenue came from radiology, 61.90% came from Andhra Pradesh, about 54.19% came from government PPP arrangements, and the largest customer contributed 44.17% of revenue.
These numbers create a clear difference between the company’s financial performance and its risk profile. The growth figures are encouraging, but the concentration figures require careful review.
The IPO price band of ₹110 to ₹118 should therefore be assessed with the final post-issue share count, earnings base and peer valuation. The reported ₹69.04 crore issue size should also be checked against the final offer document, especially because earlier material referred to a ₹45.15 crore fresh issue figure. Current IPO data shows a ₹69.04 crore total issue size.
On the available figures, it would be reasonable to describe Pramodini Medicare as a financially promising but concentration-heavy SME IPO. That is not the same as a recommendation to subscribe.
An investor who studies the IPO should pay particular attention to the final offer document, customer contracts, government PPP terms, use of IPO proceeds, post-issue share capital, valuation and liquidity conditions. These factors can materially affect the risk and return profile.
This article is for information and analysis only. It is not personal financial advice, a recommendation to buy or sell shares, or a promise of IPO allotment or market returns. Investors should review the final offer document and consider their own financial position, risk capacity and investment objectives before making any decision.
ALSO READ: Kwality Pharma Shows Strong Q3 FY26 Revenue Growth
